Aspirin resistance in patients with acute ischemic stroke

Journal of Neurology

Volumn 258, Issue 11, 2011, Pages 1979-1986

  Ozben, Serkan ^a   Ozben, Beste ^b   Tanrikulu, Azra Meryem ^b   Ozer, Feriha ^a   Ozben, Tomris ^c  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Acute stroke; Aspirin; Aspirin resistance; Ischemic stroke; Mortality; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; ANTITHROMBOCYTIC AGENT; HEPARIN;

ADULT; AGED; ARTICLE; ASSAY; BRAIN ISCHEMIA; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PREDICTION; PRIORITY JOURNAL; RATING SCALE; TREATMENT RESPONSE; DRUG RESISTANCE; MIDDLE AGED; STROKE;

AGED; ASPIRIN; DRUG RESISTANCE; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 84857684382     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6052-7     Document Type: Article

References (45)

1. Feigin VL (2005) Stroke epidemiology in the developing world. Lancet 365:2160-2161
2. Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. Lancet 371:1612-1623
3. Bogousslavsky J, Van Melle G, Regli F (1988) The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 19:1083-1092
4. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC (2005) Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 20:120-128
5. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
6. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH (1991) The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J 122:1588-1592
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349-360
8. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T (2003) Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108:542-547
9. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D (2005) Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 3:10
10. Kahraman G, Sahin T, Kilic T, Baytugan NZ, Agacdiken A, Ural E, Ural D, Komsuoglu B (2007) The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol 115:391-396
11. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83:148-158
12. Anfossi G, Russo I, Trovati M (2008) Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 6:313-328
13. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103
14. Gorog DA, Sweeny JM, Fuster V (2009) Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol 6:365-373
15. Eikelboom JW, Emery J, Hankey GJ (2010) The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. Stroke 41:2398-2399
16. Lev EI (2009) Aspirin resistance transient laboratory finding or important clinical entity? J Am Coll Cardiol 53:678-680
17. Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM (2008) A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci 15:1204-1209
18. Hohlfeld T, Weber AA, Junghans U, Schumacher M, Boucher M, Schrör K, Siebler M (2007) Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 24:43-50
19. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A (2006) Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113:31-35
20. Chen WH, Lee PY, Ng W, Tse HF, Lau CP (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43:1122-1126
21. Coleman JL, Wang JC, Simon DI (2004) Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA System. Point of Care: J Near-Patient Test Technol 3:77-82
22. Algra A, van Gijn J (1996) Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 60:197-199
23. Lee SJ, Kim TH, Kim JG, Lee BR, Chun JU, Oh GS, Lee J (2007) The prevalence of aspirin resistance and related factors in patients with ischemic stroke using the Rapid Platelet Function Assay. Stroke 38:524 (abstract)
24. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63-66
25. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM (2005) Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36:1001-1005
26. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA (2009) Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin Neurol Neurosurg 111:270-273
27. Karepov V, Tolpina G, Kuliczkowski W, Serebruany V (2008) Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovasc Dis 26:272-276
28. Jeon SB, Song HS, Kim BJ, Kim HJ, Kang DW, Kim JS, Kwon SU (2010) Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol 64:51-57
29. Englyst NA, Horsfield G, Kwan J, Byrne CD (2008) Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 28:1196-1203
30. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965
31. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655
32. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007
33. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, Simon DI (2003) Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92:1492-1494
34. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilotstudy including 180 post-stroke patients. Thromb Res 71:397-403
35. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH, American Heart Association, American Stroke Association (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39:1647-1652
36. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195-198
37. Zytkiewicz M, Giełwanowska L, Wojtasińska E, Psuja P, Zawilska K (2008) Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 118:727-733
38. Geisler T, Gawaz M (2008) Resistance to antiplatelet sub-stances - a real clinical problem. Herz 33:260-268
39. Hankey GJ, Eikelboom JW (2004) Aspirin resistance. BMJ 328:477-479
40. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682-1687
41. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717
42. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH investigators (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331-337
43. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU (2010) Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol 17:434-442
44. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM (2005) Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16:269-280
45. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM (2008) Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 19:119-124